Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

In vitro metabolism of the lignan (-)-grandisin, an anticancer drug candidate, by human liver microsomes

Full text
Author(s):
Barth, Thiago [1, 2] ; Habenschus, Maisa Daniela [3] ; Moreira, Fernanda Lima [4] ; Ferreira, Leandro De Santis [5] ; Lopes, Norberto Peporine [1] ; Moraes de Oliveira, Anderson Rodrigo [3]
Total Authors: 6
Affiliation:
[1] Univ Sao Paulo, Nucleo Pesquisa Prod Nat & Sintet, Fac Ciencias Farmaceut Ribeirao Preto, BR-14040903 Ribeirao Preto, SP - Brazil
[2] Univ Fed Rio de Janeiro, Curso Farm, BR-27930560 Macae, RJ - Brazil
[3] Univ Sao Paulo, Fac Filosofia Ciencias & Letras Ribeirao Preto, Dept Quim, BR-14040901 Ribeirao Preto, SP - Brazil
[4] Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-14040903 Ribeirao Preto, SP - Brazil
[5] Lychnoflora Pesquisa & Desenvolvimento Prod Nat L, BR-14030090 Ribeirao Preto, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: DRUG TESTING AND ANALYSIS; v. 7, n. 9, p. 780-786, SEP 2015.
Web of Science Citations: 6
Abstract

(-)-grandisin is a tetrahydrofuran lignan that displays important biological properties, such as trypanocidal, anti-inflammatory, cytotoxic, and antitumor activities, suggesting its utility as a potential drug candidate. One important step in drug development is metabolic characterization and metabolite identification. To perform a biotransformation study of (-)-grandisin and to determine its kinetic properties in humans, a high performance liquid chromatography (HPLC) method was developed and validated. After HPLC method validation, the kinetic properties of (-)-grandisin were determined. (-)-grandisin metabolism obeyed Michaelis-Menten kinetics. The maximal reaction rate (V-max) was 3.96 +/- 0.18 mu mol/mg protein/h, and the Michaelis-Menten constant (K-m) was 8.23 +/- 0.99M. In addition, the structures of the metabolites derived from (-)-grandisin were characterized via gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) analysis. Four metabolites, 4-O-demethylgrandisin, 3-O-demethylgrandisin, 4,4-di-O-demethylgrandisin, and a metabolite that may correspond to either 3,4-di-O-demethylgrandisin or 3,5-di-O-demethylgrandisin, were detected. CYP2C9 isoform was the main responsible for the formation of the metabolites. These metabolites have not been previously described, demonstrating the necessity of assessing (-)-grandisin metabolism using human-derived materials. Copyright (c) 2015 John Wiley \& Sons, Ltd. (AU)

FAPESP's process: 09/51812-0 - Development of a platform for the study of in vitro and in vivo metabolism of natural products, a need for pre-clinical testing system
Grantee:Norberto Peporine Lopes
Support type: BIOTA-FAPESP Program - Thematic Grants
FAPESP's process: 13/17658-9 - Development and validation of chromatographic and electrophoretic methods for subsequent application in studies of in vitro metabolism and biotransformation - phase 2
Grantee:Anderson Rodrigo Moraes de Oliveira
Support type: Regular Research Grants